Clinical Trials Logo

Filter by:
NCT ID: NCT05764889 Enrolling by invitation - Circumcision, Male Clinical Trials

Study on the Protective Effect of a Flexible Sleeve Penis Protection Device on Penis After Circumcision

Start date: March 15, 2023
Phase: N/A
Study type: Interventional

Circumcision is a common clinical procedure for both circumcision and phimosis, which are common disorders of the male reproductive system. For post-circumcision patients, a flexible sleeve penile protection device was invented as a modification of the traditional gauze bandage. This study investigated the protective effect of the device by recruiting post-circumcision patients to use the device and collecting indicators related to post-operative recovery and patients' experience of using the device.

NCT ID: NCT05760677 Enrolling by invitation - Clinical trials for PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Study on the Efficacy and Safety of Chiglitazar Sodium in PCOS With T2DM

Start date: October 1, 2022
Phase: Phase 1
Study type: Interventional

Purpose and significance: To explore the clinical efficacy and safety of Chiglitazar sodium in polycystic ovary syndrome with type 2 diabetes Methods: From October 2022 to September 2024, a total of 142 PCOS with T2DM patients admitted to Department of Endocrinology and Metabolism at the Affiliated Hospital of Nantong University were recruited. Participants are randomized in a ratio of 1:1 into two treatment groups of 71 participants: ① control group;②experimental group. After randomization, the control group was treated with lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone, and the patients in the experimental group were treated with lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar (32mg QD) until the end of follow-up. The treatment and follow-up period totaled 3 months. Observe the body weight, menstrual cycle and blood glucose control and other related indicators. Type of study: randomized controlled, prospective, intervention study.

NCT ID: NCT05749341 Enrolling by invitation - Endometriosis Clinical Trials

A Liquid Biopsy Diagnostic Techniques for Endometriosis

Start date: April 10, 2023
Phase:
Study type: Observational

To evaluate the diagnostic efficiency of circulating endometrial cell detection method using microfluidic chip as an non-invasive method for diagnosis in endometriosis.

NCT ID: NCT05748262 Enrolling by invitation - COVID-19 Clinical Trials

Characteristics of SARS-CoV-2 Reinfection

Start date: December 15, 2022
Phase:
Study type: Observational

As the COVID-19 pandemic continues and the number of individuals with previous infection rises, numbers of SARS-CoV-2 reinfection are increasing. The second Omicron wave in Shanghai, China caused by BA.5-sublineages led to a large fraction of reinfections among BA.2 primary infections. To better understand the SARS-CoV-2 reinfection rate and clinical severity of reinfections, the investigators conducted a multi-centre cohort study. The investigators hope to provide valuable clinical evidences for reinfections and offer guidance for future policy making.

NCT ID: NCT05739500 Enrolling by invitation - Glioma Clinical Trials

MRI-based Computer Aided Diagnosis Software (V1) for Glioma

Start date: December 1, 2022
Phase:
Study type: Observational

The goal of this multi-center clinical trial is to evaluate the effectiveness of MRI-based computer-aided diagnosis software (V1) for glioma segmentation, gene prediction, and tumor grading. Machine learning methods such as high-precision tumor segmentation and classification and discrimination modeling can further optimize the non-invasive molecular diagnosis and prognosis prediction. The main question it aims to answer is whether the software can predict the molecular type and the prognosis quickly and correctly. The results will be compared with the real-world clinical data double-blindly. Finally, form a set of user-friendly automatic glioma diagnosis and treatment systems for clinics.

NCT ID: NCT05733533 Enrolling by invitation - Clinical trials for Refractory Chronic Cough

A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough

Start date: March 9, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II study that will investigate the efficacy, safety and tolerability of HRS-2261 in subjects with refractory chronic cough using a double blind, placebo controlled, randomized study design.

NCT ID: NCT05724290 Enrolling by invitation - Rhinitis, Allergic Clinical Trials

Mechanism of EGR2 in Allergic Rhinitis

Start date: January 30, 2023
Phase: Phase 1
Study type: Interventional

EGR2 may be a target for the treatment of nasal polyps.

NCT ID: NCT05718401 Enrolling by invitation - Multiple Myeloma Clinical Trials

The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics

Start date: November 1, 2022
Phase:
Study type: Observational

In this clinical study, a single-center retrospective cohort study was used to explore the clinical characteristics and risk factors of patients with multiple myeloma myocardial amyloidosis. An exploratory study was conducted to compare the effects of various sublayer factors (M protein, electrocardiogram, echocardiography, CD138, chromosome abnormalities, etc.) on patients' survival. On this basis, a hierarchical diagnostic model (1-2-3-4) for patients with multiple myeloma complicated with myocardial amyloidosis was established based on the phenoomics of NMR and mass spectrometry, and the prognosis was evaluated simultaneously, in order to create an early, non-invasive, sensitive and quantitative diagnostic model for multiple myeloma complicated with myocardial amyloidosis, and lay a foundation for the early application of effective treatment.

NCT ID: NCT05716984 Enrolling by invitation - Clinical trials for Group 3 Pulmonary Hypertension

rhBNP in Type 3 Pulmonary Hypertension

Start date: April 15, 2023
Phase: Phase 4
Study type: Interventional

Pulmonary hypertension is a common clinical syndrome, which seriously affects the quality of life and survival of patients. Pulmonary hypertension (PH) is defined as an increase in mean pulmonary arterial pressure (mPAP) to ≥20 mmHg at rest as measured invasively by right heart catheterisation (RHC). Pulmonary hypertension can be divided into five types, among which pulmonary hypertension caused by chronic pulmonary diseases and/or hypoxia is called Group 3 pulmonary hypertension, which is the most important factor of pulmonary heart disease. The drugs currently used to treat patients with PAH (prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, sGC stimulators) have not been sufficiently investigated in Group 3 PH, except indirect treatment methods such as improving hypoxia and controlling infection. Recombinant human brain natriuretic peptide (rhBNP) is a biological agent with a molecular weight of 3664Da synthesized by DNA technology. It is availble in China. It has many functions such as diuresis, vasodilation, inhibition of renin-angiotensin-aldosterone and sympathetic nervous systems, etc. RhBNP has been suggested in patients with acute myocardial infarction and congestive heart failure. In view of the dilating effect of rhBNP on pulmonary vessels, it is speculated that rhBNP may reduce type 3 pulmonary hypertension. Based on this hypothesis, we conducted a preliminary clinical trial. The results showed that, compared with the placebo group, after rhBNP was continuously pumped for 24 hours, the pulmonary artery hemodynamic indexes continuously monitored by Swan-Ganz catheter were significantly improved. In view of the pharmacological effect of rhBNP and our previous clinical trial results, this study intends to conduct a prospective, multicenter, placebo-controlled, double-blind clinical trial to evaluate the efficacy and safety of rhBNP in the treatment of patients with group 3 pulmonary hypertension.

NCT ID: NCT05698550 Enrolling by invitation - Infertility, Female Clinical Trials

The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET

Start date: September 15, 2023
Phase: Phase 3
Study type: Interventional

This randomized controlled trial aims to determine whether Erzhi Tiangui Formula can optimize the reproductive outcomes of elderly patients with expected poor ovarian response, and to provide a new approach to traditional Chinese medicine assisted in vitro fertilization and embryo transfer (IVF-ET).